Belinostat resolves skin barrier defects in atopic dermatitis by targeting the dysregulated miR-335:SOX6 axis

Loss of epidermal microRNA, miR-335, causes skin barrier defects in atopic dermatitis. Belinostat, a histone deacetylase inhibitor, restores miR-335 expression and represents a potential therapeutic for treatment of atopic dermatitis.

Source: Journal of Allergy and Clinical Immunology - February 19, 2020 Category: Allergy & Immunology Authors: Wen Chiy Liew, Gopinath M. Sundaram, Shan Quah, Lum Guo Guang, Jonathan S.L. Tan, Rajkumar Ramalingam, John E.A. Common, Mark B.Y. Tang, E. Birgitte Lane, Steven Thng, Prabha Sampath Source Type: research